MENU
RemediumOne facilitated a discussion with Prof. Craig Anderson, Director, Brain Health Program, The George Institute for Global Health (TGI), as part of the ongoing preparations for the ACT GLOBAL trial to be conducted in Sri Lanka. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global, adpative platform trial for stroke.
Stroke remains a leading cause of death and disability worldwide. Despite advances in medical technology and treatment strategies, many patients still do not achieve optimal outcomes. The George Institute’s ACT-GLOBAL study is an adaptive platform trial that is aiming to address the urgent need for the development of new and more effective interventions for stroke patients across the world.
A platform trial involves study of several different clinical questions at the same time, essentially uniting multiple clinical trials or ‘Domains’ under a single organisational structure lead by experts in the field. Adaptive design allows the team to add or collapse (if needed) research questions during the trial as more information is collected. We believe the adaptive platform approach is a uniquely flexible and efficient way to conduct ground-breaking research.
Current Domains include:
The hybrid session brought together the Principal Investigators, senior registrars medical officers, ETU consultants and the RemediumOne team with PIs joining both in-person at the Epilepsy Unit, NHSL and virtually from various locations. Prof. Craig presented an in-depth overview of the study protocol, followed by an interactive Q&A session, where we explored both the potential impact and the practical challenges of conducting this trial.
We extend our sincere thanks to Prof. Craig and the team at The George Institute for Global Health for their collaboration.
